|
نوع |
منشور |
| 248 |
مجلة |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 300 |
مجلة |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 384 |
مجلة |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632. |
| 660 |
مجلة |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 738 |
مجلة |
Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584. |
| 921 |
مجلة |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1041 |
مجلة |
Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951. |
| 1057 |
مجلة |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1058 |
مجلة |
Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Am J Hosp Pharm 1983 ; 40: 1690-1691. |
| 1084 |
مجلة |
Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O.
Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies.
Lancet 1988 ; 1(8587): 700. |
| 1221 |
مجلة |
Dahlin PA, Paredes SM.
Visual compatibility of dobutamine with seven parenteral drug products.
Am J Hosp Pharm 1980 ; 37: 460,464. |
| 1625 |
مجلة |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1802 |
مجلة |
Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194. |
| 1914 |
مختبر |
Pemetrexed (Alimta®) - Summary of Product Characteristics
Eli Lilly 2016 |
| 2090 |
مجلة |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2108 |
مجلة |
Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232. |
| 2295 |
مختبر |
Fosaprepitant (Emend®) - Summary of Product Characteristics
Merck Sharp Dohme 2013 |
| 3012 |
مجلة |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3216 |
مجلة |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
مجلة |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3307 |
مجلة |
Kiser T.H, Barber G.R, Robinson A.
Managing the intravenous calcium shortage: Evaluation of calcium chloride stability in 0.9% sodium chloride and dextrose 5% water polyvinyl chloride bags.
Hosp Pharm 2012 ; 47, 1: 27-30. |
| 3408 |
مجلة |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3523 |
مختبر |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018 |
| 3546 |
مختبر |
Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007 |
| 3619 |
مختبر |
Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics
Wockhardt 2016 |
| 3621 |
مختبر |
Phosphate dipotassique - Résumé des caractéristiques du produit
Renaudin 2008 |
| 3622 |
مجلة |
Weeks Phillip A, Teng Yang, Wu Lei, Sun Mary, Yang Zhen, Chow Diana S-L.
Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride.
Int J Pharm Compound 2014 ; 18, 2 : 152-158. |
| 3634 |
مختبر |
Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
Accord Healthcare 2011 |
| 3662 |
مختبر |
Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014 |
| 3753 |
مختبر |
Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics
Cubist Pharmaceuticals 2014 |
| 3766 |
مجلة |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
مجلة |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3791 |
الملصق |
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014 |
| 3824 |
مجلة |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
الملصق |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
الملصق |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
الملصق |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3838 |
مختبر |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 3883 |
مختبر |
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016 |
| 3933 |
مختبر |
Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit
Teva Laboratoire 2015 |
| 3948 |
مجلة |
Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424. |
| 3964 |
مجلة |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 4055 |
مجلة |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 |
مجلة |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4154 |
مختبر |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4319 |
مجلة |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4433 |
مجلة |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4434 |
مجلة |
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170. |
| 4524 |
الملصق |
Stucki C, Sautter A-M, Bonnabry P.
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.
ESCP Symposium, Geneva, Switzerland 2009 |
| 4603 |
مجلة |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4654 |
الملصق |
Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021 |
| 4698 |
مجلة |
Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022 |
| 4720 |
مختبر |
Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021.
Paratek Pharmaceuticals 2021 |
| 4732 |
مجلة |
Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E.
Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
Am J Health-Syst Pharm 2023 80, 3;164–170 |
| 4742 |
مجلة |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 |
مجلة |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1: |
| 4802 |
مختبر |
Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit
Aguettant Laboratory 2021 |
